Posted by Michael Wonder on 03 Mar 2022
Amneal enters U.S. biosimilars market with approval of Releuko (filgrastim-ayow)
1 March 2022 - First of three Amneal biosimilars expected for U.S. approval and launch in 2022.
Amneal Pharmaceuticals today announced the U.S. FDA approval of the biologics license application for filgrastim-ayow, a biosimilar referencing Neupogen.
